Sun Pharmaceuticals Industries announced that one of the wholly owned subsidiaries of the Company has agreed to
acquire by way of allotment to it, 428,571 ordinary shares (equivalent to 12.5% fully diluted
equity stake) of WRS Bioproducts, Australia, a company that is developing novel
technologies to produce and commercialize supplements and nutraceutical ingredients from
diverse algae species in Australia. The cost of acquisition is AUD 2 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
